adrenalin activates the ␤-adrenergic receptor, which results in coupling of the ␣ subunit of Gs protein to adenylate cyclase (AC) and in turn increases AC activity, followed by an increase in cAMP and the activation of PKA in subcellular microdomains. Sustained activation of the ␤-receptor results in receptor phosphorylation by ␤-adrenergic kinase and is processed toward inactivation (desensitization) (30). PKA phosphorylates at least three key Ca 2+ regulators, i.e., LTCC, RyR, and PLN, which enhances Ca 2+ influx, increases the velocity and the amplitude SR Ca 2+ release, and augments SERCA pump activity, respectively. PKA, thus, is a major regulator of cardiac contractile and relaxation functions (108). Intriguingly, these three PKA targets of Ca 2+ cycling regulation are also major cardiac substrates of CaMK II. The major isoform of cardiac CaMK II is II␦ (31) splice variants of which shares distinctive subcellular localizations; i.e., II␦C is in the cytosol, whereas II␦B localizes in the nuclei due to its nuclear localization signal near its amino terminal (31). CaMK II regulates cardiac Ca 2+ cycling throughout the phosporylation of LTCC, RyR, and PLN; CaMK II-dependent phosphorylation of the sodium channel (95) and the potassium channel (92) indirectly modulates cardiomyocyte excitation-contraction (E-C) coupling. Presumably, CaMK II is regulated by Ca 2+ oscillation itself (65, 114); however, it is not entirely clear which component of Ca 2+ regulates CaMK II activities in cardiomyocytes and how.
transients, fundamentally govern contraction and relaxation in cardiomyocytes. Briefly, membrane depolarization triggers Ca 2+ influx through L-type Ca 2+ channels (LTCC), followed by a Ca 2+ -induced Ca 2+ release (CICR) through the ryanodine receptors (RyR) (6) . Although the LTCC is being rapidly inactivated by the local elevation of Ca 2+ and sustained membrane depolarization, transiently induced cytosolic Ca 2+ binds to the thin filament troponin C and activates the contractile machinery. As sarcoplasmic retiulum (SR) Ca 2+ content is being depleted, RyRs are inactivated, switching the cardiomyocyte from a systolic to diastolic mode. During the diastolic period, cytosolic Ca 2+ ions are resequestered into the SR by SERCA2a or pumped out from the cell by the sarcolemmal Na + -Ca 2+ exchanger (NCX). The relative contribution of SERCA2a and NCX to Ca 2+ efflux depends on the animal species. Ca 2+ uptake through the SERCA pump is negatively regulated by phospholamban (PLN). Ca 2+ -dependent intracellular Ca 2+ homeostasis through these nodal components has been extensively reviewed elsewhere (6) . PP1 and PP2A share highly similar sequences in the catalytic domain, PP1 appears to have a higher affinity for the dephosphorylation of Ca 2+ cycling regulators including LTCC, RyR, and PLN (64) , whereas PP2A has been mainly attributed to the dephosphorylation of myofibrillar proteins such as troponin I and myosin binding protein C (69) .
In the failing hearts, it has increasingly become clear that altered phosphorylation level of these phosphoproteins by kinases/phosphatases is initially driven by a compensatory mechanism to adjust cardiac output to meet metabolic demands of the body, and it may eventually become maladaptive and further lead to deleterious Ca 2+ homeostasis (45, 108) . Therefore, molecular targeting of these phospho-regulatory proteins as well as these kinase/phosphatases can be potentially therapeutic targets for heart failure, as described below.
Compartmentation of the PKA Signal Cascade
Phosphorylation of Ca 2+ cycling in cardiomyocytes is governed by a complex intracellular spatial and temporal set of signals, and defects in their compartmentation seem to play a significant role in cardiac disease. PKA signaling is compartmented at multiple levels in a cascade, i.e., through isoform-specific subcellular localization of G-protein coupling (30), adenylate cyclases (35), PKA anchoring proteins (27), and cyclic nucleotide phosphodiesterases (35, 111) . Compartmentation of cardiac membrane receptor signaling and its physiological significance are becoming ever more recognizable (52, 91) . A typical example of receptor compartmentation has been found in the ␤ 1 -AR and the ␤ 2 -AR (15, 103). Both ␤ 1 -AR and ␤ 2 -AR couple with the G ␣s -cAMP-PKA cascade, and it has been well documented, during progression of heart failure, that expression patterns and ratios of ␤ 1 -AR and ␤ 2 -AR change. Intriguingly, ␤ 1 -AR activation leads to inotropic and lusitropic responses; However, ␤ 2 -AR activation enhances the amplitude of the Ca 2+ transient and twitch in cardiomyocytes without an acceleration in relaxation. ␤ 2 -AR activation indeed fails to induce phosphorylation of PLN. Such ␤ 1 -AR and ␤ 2 -AR distinction has been explained, at least in part, by their spatial compartmentation; at rest ␤ 2 -AR is confined in caveolae, where this receptor is closely associated with LTCC, whereas the ␤ 1 -AR distributes globally on the sarcolemma, and the vast majority are 7 PHYSIOLOGY CaMK II are segregated. Such local Ca 2+ changes are indeed hard to measure using micro-electrodes and fluorescent Ca 2+ indicator technologies. Furthermore, as mentioned, CaMK II activation has been directly linked to ␤-adrenergic stimulation (118), and isoproterenol-induced cardiomyocyte apoptosis is inhibited by pharmacological CaMK II inhibition. In addition, the adaptor molecule that localizes CaMK II at the corresponding subcellular microdomain has not been well characterized, whereas that of PKA signaling is demonstrated to be a family of AKAP proteins. For example, RyR and CaMK II are known to make macromolecular protein complexes along with PKA, PP1, and PP2A, but CaMK II anchoring protein to RyR has not yet been identified. The significance of the local activation of CaMK II in cardiac hypertrophy and heart failure was shown in a study on the role of the nuclear ␦B isoform in the induction of a pattern of hypertrophic gene expression (115) , whereas the cytoplasmic ␦C isoform significantly affected E-C coupling through phosphorylation of the RyR (116) . Although the importance of CaMK II regulation in the failing heart was confirmed by a study by Anderson and colleagues (113) , which showed that the inhibition of CaMK II in infarct models can prevent the progression of adverse cardiac remodeling, although the study did not identify what fraction of CaMK II was involved in this treatment. (96), also regulates cardiac PP1 activity in cardiomyocytes (38). We assume that an imbalance of these kinases and phosphatase-dependent regulation of Ca 2+ cycling in a local environment is critically involved in the progression of heart failure and associated arrhythmia, as discussed below.
Phosphatases Locally

Protein Phosphatase 1 is Abnormally Regulated in Heart Failure
In heart failure, the increase in global and SR-associated PP1 activity has been linked to depressed SR Ca 2+ pump activity (37, 48). Herein, depressed phosphorylation levels of PLN may play a role. Although details have yet to be clarified, the mechanism of augmented PP1 activity is in part explained by either loss of endogenous inhibitory subunits or upregulation of the PP1 catalytic subunit. Namely, decreased expression level of INH-1 (38), decreased phosphorylation level of INH-1 at Thr35 (32), decreased activity of INH-2(38), and increased expression of the PP1 catalytic subunit associated with SR preparation (104) are reportedly involved. As shown in FIGURE 2, PP1 activity progressively increases both in the cytosol and SR preparations and correlates well with development of cardiac dysfunction (104) . In addition, the role of PP1 hyperactivity in heart failure is supported by the finding of Carr et al. that the overexpression of the PP1 catalytic subunit ␣ in the mouse heart caused dilated cardiomyopathy (13 With relation to these changes of PP activities in the failing heart, it has been suggested that increased PP1 and PP2A activities are the compensatory mechanism to facilitate myofilament contraction against PKC-mediated hyperphophorylation of myofilament phosphoproteins, which cause decrease in Ca 2+ sensitivity (4, 77) . Apparently, in this regard, further investigation regarding increased protein phosphatase regulation remains to be performed.
RyR Hyperphosphorylation by PKA and CaMK II: Cause of Leaky SR?
Dysregulation of the RyR by hyperphosphorylation in heart failure is characterized by improper gating of SR Ca 2+ release and the diastolic Ca 2+ leak. This concept has been pioneered by Marks's group (67) . Marks and colleagues reported that hyperactivation of PKA causes increased phosphorylation at Ser2809 of RyR, thereby inducing dissociation of FKBP12.6 from RyR, followed by instability of the RyR channels (67) . In this regard, studies from Marks' group and Yano et al. (110) found that altered stoichiometry between FKBP12. 6 and RyR leads to a SR Ca 2+ leak and cardiac contractile dysfunction. Nevertheless, the working model that RyR-FKBL12. are detrimental factors that aggravate SR Ca 2+ cycling and confer a heart failure phenotype. Indeed, Braz et al. (12) reported that PP1 activity is potentially enhanced in heart failure by excessive neurohumoral stimuli involving noradrenalin, angiotensin II, and endothelin, all of which are initially adaptive but become maladaptive as heart failure progresses. These stimuli activate Gq-coupled receptors and in turn cause activation of protein kinase C␣ (12, 41), which phosphorylates INH-1 at its Ser67 residue, thereby activating PP1 (12, 80), leading to dephosphorylation of PLN.
Notably, however, increased global or SR-associated PP1 activity does not always cause hypophosphorylation of Ca 2+ cycling regulators in failing hearts. Marks and colleagues found that RyR is hyperphosphorylated in the animal and human failing hearts. According to their study, the RyR-associated PP1 protein level is decreased compared with that of PKA; therefore, they speculated that the local balance of kinase and phosphatases is more critical for causing hyperphosphorylation of RyR compared with the global increase in PP1 activity (60, 67) . This notion was further supported by the finding by Yano et al. (109) showing that "hypo"phosphorylation of PLN and "hyper"phosphorylation of RyR coexist within the same failing cardiomyocytes (see FIGURE 3 for heterogeneous phosphorylation balance in the failing heart SR). These findings suggest that phosphatase activity in subcellular microdomains is critical in failing cardiomyocytes. Indeed, LTCC (16) and NCX (99) were also found to be REVIEWS FIGURE 3. Schematic image of sarcoplasmic reticulum microenvironment Interestingly, the growing interest in RyR phosphorylation had led several investigators (2, 36, 57) to propose that CaMK II, instead of PKA, is critical for RyR phosphorylation and the associated SR Ca 2+ leak. Curran et al. (23) found that activated CaMK II through ␤-adrenergic stimulation is responsible for the SR Ca 2+ leak, but not by PKA activation. The frequent Ca 2+ sparks and decrease in SR Ca 2+ content found in CaMK II transgenic mice support this leak mechanism. However, this is still an emerging research area, and more work is needed to untangle the complexity of CaMK II-dependent RyR phosphorylation. For example, the CaMK II-mediated hyperphosphorylation effect on RyR has been questioned by a recent study (107) that showed that CaMK IIdependent phosphorylation suppressed Ca 2+ sparks and Ca 2+ waves in cultured rat cardiomyocytes. However, the conflicting results among these studies might be explained by differences in the experimental settings, including distinct molecular functions between cell types and animal species, a difference between intact and permeabilized sarcolemma, which may affect subcellular compartmentalization of cyclic nucleotides, and the artificial substrates selected for various experimental strategies to overexpress molecules (88, 105) . Additional complexity has been found in the ongoing debates with regard to phosphorylation sites of RyR that are critical for the RyR Ca 2+ leak in the failing heart. Other than the originally reported Ser2808/2809 (shared animo acids with a putative PKA site), there are several candidate CaMK II phosphorylation sites in RyR, e.g., Ser2815 (a newly identified CaMK II site) (98, 102) .
Other Molecular Players Regulating RyR Phosphorylation
As reported by Marks's group and other investigators, the SR Ca 2+ -releasing channel is composed of a megaprotein complex (7) that includes the RyR tetramer, FKBP12.6 (calstabin2), PKA, PP1, PP2A, calmodulin, CaMK II, and phosphodiesterase (PDE)4D3, and this molecular conglomerate physically associates with other structural proteins including sorcin (34, 70), homer (101), triadin, junction, calsequestrin (112) , and histidine-rich Ca 2+ binding protein (59) . Lehnart et al. (60) found that a lack of PDE4D3 by gene targeting caused adult-onset progressive cardiomyopathy in mice. In PDE4D3-deficient mice, the RyR displayed hyperphosphorylation at Ser2808, and RyR channels were found to be leaky. Since PDE4D3 expression is downregulated in human failing hearts, Lehnart et (105) . A RyR mutant mouse lacking CaM binding sites exhibits early onset progressive cardiac hypertrophy, reduced contractility, and premature death. CaM mutant RyR is characterized by a lack of termination of SR Ca 2+ release in cardiomyocytes, suggesting the essential role of CaM binding to RyR for SR Ca 2+ inactivation. Notably, calmodulin-dependent dual regulation (i.e., CaMK II-depedent and direct modulations) has also been noted in LTCC (9); thus Ca 2+ apparently regulates E-C coupling utilizing multiple pathways. Perhaps the duration and specific distribution of modulation differ between direct regulation and regulation through kinase activity.
Regulation of Ca 2+ Uptake and Its Link to Heart Failure
In addition to the reduced expression of the SERCA2a protein found in failing hearts (42, 62, 79, 84), phosphorylation of PLN clearly affects SR Ca 2+ uptake. Human genetic studies strongly support this notion. The R9C mutation (86) disrupts PKA phosphorylation in PLN, suppresses oligomerized wild-type PLN phosphorylation, and causes dilated cardiomyopathy. The R14del mutation, on the other hand, is super-inhibitory, only partially responding to PKA phosphorylation, and leads to severely dilated cardiomyopathy and heart failure (39). PLN was found to be hypophosphorylated at the Ser16 residue, a PKA phosphorylation site, in several studies that tested failing hearts, in clear contrast to hyperphosphrylated RyR by PKA (73, 83, 87, 109) . As such, PLN is generally dephosphorylated and inactive to stimulate SERCA2a, probably due to the increased PP1 activity, although several animal models failed to reproduce these reported changes (10, 75). The Thr17 residue of PLN is reported to be reduced in heart failure (74, 75) , although cardiac CaMK II␦ expression and activity are found to be increased (43, 56) .
Interacting proteins with the SERCA/PLN complex include sarcolipin (SLN) (8), S100A1 (54), RGL (5), Initially, NCX functions as a compensatory mechanism and keeps cellular Ca 2+ level constant by upregulation of Ca 2+ efflux in association with decreased SERCA pump activity. However, this compensatory mechanism eventually becomes maladaptive because decreased SR Ca 2+ content decreases the amplitude of Ca 2+ transient and cardiac contractility. In addition, NCX activity is indirectly linked to Na-K-ATPase that has an accessory protein, phospholemman (PLM), a trans-sarcolemmal protein that has a single phosphorylated peptide residue, which has long been known as a major PKA substrate in the cardiac membrane fraction. PLM expression is found to be decreased and hyperphosphorylated at its Ser68 residue in heart failure, thereby inducing less inhibition of Na-KATPase and indirectly affecting NCX (11).
Therapeutic Approach and Clinical Implication: Pump Up or Seal the Leak?
Calcium cycling defects serve as potential therapeutic molecular targets for heart failure. However, to date, none of the pharmaceutical agents (small molecular compounds) has sufficient target specificity to ameliorate this abnormal Ca 2+ cycling in heart failure (19). PDE inhibitors have been extensively used to treat acute cardiac decompensation; however, several large-scale clinical trials failed to support its chronic therapeutic efficacy, which is likely due to its spatiotemporal nonspecificity in modulating the various PKA targets. Accordingly, many efforts have been made to correct defective Ca 2+ cycling in the settings of experimental failing hearts by genetically engineered techniques or a vector-mediated gene transfer, although the clinically relevant therapeutic framework has not been established yet. Overexpression of specific subtypes of adenylyl cyclase to enhance cardiac cAMP production has been tested in small and large animal models of heart failure (58, 82) . Intriguingly, therapeutic benefit of adenylyl cyclase VI was linked to selective phosphorylation of PLN in murine model of heart failure (58). Intriguingly, RyR phosphorylation was suppressed in adenylyl cyclase VI cardiac transgenic mice.
Direct benefits of a selective enhancement of PLN phosphorylation to treat heart failure have been supported by the PLN pseudo-phosphorylated mutant (S16EPLN) therapy from our group (44, 46, 47, 50, 71). The therapeutic efficacy of this pseudo-phosphorylation therapy has been apparent in cardiomyopathic hamsters, postmyocardial infarct rat hearts with chronic heart failure, and failing hearts resulting from continuous rapid pacing in sheep (53). Ongoing clinical studies employing intracoronary AAV directed delivery to overexpress SERCA2 in patients with advanced heart failure are currently in progress (1) (68), and myotonic dystrophy protein kinase (DMPK) (51). Among these, sorcin, a penta EF hand family protein, is regulated by PKA and PP1, and altered in the hamster heart failure animal model (68) . Reduction of S100A1 in myocardial infarction and heart failure was found to be associated with depressed SR Ca 2+ cycling in heart failure (8). An upregulation of SLN (3, 72) , the transmembrane protein that has highly homologous sequence with PLN, suppresses SERCA2a activity. Kaliman et al. reported that loss of DMPK led to PLN dephosphorylation and reduced Ca 2+ uptake (51). The phospho-regulation of S100A1 and SLN has not been established. Wei et al. (100) reported that NCX activity is also regulated by phosphorylation through PKA and PP1. In heart failure, NCX is found to be hyperphosphorylated due to reduction of NCX-associated PP1 (100). breakthrough in biologically targeted therapy for advanced heart failure.
Correction of abnormal phosphatase regulation is another therapeutic approach for upregulating SR Ca 2+ uptake in heart failure (FIGURE 4). Our group reported that INH-2, an endogenous PP1 inhibitory protein, can selectively decrease the SR microvesicleassociated PP1 activity, perhaps by translocating the PP1 catalytic subunit from the SR to the cytosol, thereby increasing PLN phoshsphorylation and upregulating SR Ca 2+ uptake in the cardiomyopathic hamster heart failure model (104) . In addition, it is important that RyR phosphorylation was unaltered in the INH-2 delivered heart failure model. Consequently, overexpression of INH-2, a cytosolic PP1 inhibitor, may correct an abnormal subcellular PP1 environment and restore defective SR Ca 2+ cycling.
The amelioration of SR Ca 2+ uptake activity not only improves the speed of Ca 2+ removal during relaxation but also increases the SR Ca 2+ content, and therefore the amount of released Ca 2+ contributes to the enhancement of cardiac contraction, which is somehow contradictory of the general perception of the inappropriateness of using inotropic therapies to treat heart failure. Indeed, there is a controversy regarding the functional role of upregulating SR Ca 2+ flux. Indeed, in certain forms of genetic cardiac hypertrophy (25, 89), PLN ablation failed to rescue cardiac dysfunction, although cellular contractility showed significant improvement (89) . In addition, hyperactivation of SR Ca 2+ uptake by ablating PLN and substituting SERCA2a with SERCA2b, an isoform with higher Ca 2+ affinity compared with SERCA2a, caused pathological hypertrophy and reduced lifespan (93) , and endogenous PLN seems to play a protective role on cardiac injury in that model. With relation to this, one of the mutations of PLN, Leu39stop, proposed as PLN null-equivalency (40) due to the lack of transmembrane domain, has been linked to human dilated cardiomyopathy. Although mechanisms and associated experimental conditions of these negative phenotypes need to be further considered in future experiments, these data suggest that overactivation of Ca 2+ flux far beyond the normal Ca 2+ homeostasis throughout the lifespan is associated with cardiac injury in certain situations. Also, it seems clear that upregulation of SR Ca 2+ uptake cannot compensate pathophysiological signaling, which primarily causes cardiac hypertrophy. Further validation and optimization of Ca 2+ uptake targeting therapy in heart failure will be needed.
RyR stabilization is another framework to ameliorate impaired SR Ca 2+ handling. As RyR is being hyperphosphorylated by PKA or CaMK II in the failing heart, the channel becomes unstable and leaky. A recently identified chemical compound, JTV519, reduces SR Ca 2+ leak and improves cardiac function in a canine pacing-induced heart failure model (109) . Intriguingly, JTV516 is apparently not a direct phosphorylation modifier but rather a channel stabilizer based on its benzodiazepine-like structure, suggesting that the local environment in the immediate vicinity of the RyR complex is critical for proper RyR phospho-regulation and normal channel gating. Furthermore, JTV is effective for preventing fatal arrhythmia induced by excessive ␤-adrenergic stimulation in the FKBP12.6-deficient mice (97) , which mimics genetic arrhythmia-susceptible heart conditions. CaMK II inhibition also is receiving attention as a new treatment strategy for preventing heart failure progression. Because CaMK II hyperactivation is directly linked to improper phospho-regulation of RyR and leaky SR, modification of this kinase may also be useful to seal the leaky Ca 2+ releasing channels. Indeed, Anderson and colleagues documented that chemical or genetic inhibition of CaMK II prevents adverse cardiac remodeling in isoproterenol-induced mouse cardiomyopathy (113) . Further study will be needed for its clinical application.
In summary, Ca 2+ cycling defects in heart failure are characterized by impaired SR Ca 2+ release and associated Ca 2+ leak, reduced SR Ca 2+ uptake, and reduced Ca 2+ transients. Molecular targeting approaches to correct these abnormalities hold promise as a new therapeutic modality in the advanced end-stage heart failure patients who are less suited to the currently available medical therapy due to the severely impaired cardiac contractility and associated low blood pressure. Further progress in understanding of Ca 2+ cycling defects with relevant application in the clinical setting are keenly anticipated.
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